JP2022535429A5 - - Google Patents

Info

Publication number
JP2022535429A5
JP2022535429A5 JP2021571993A JP2021571993A JP2022535429A5 JP 2022535429 A5 JP2022535429 A5 JP 2022535429A5 JP 2021571993 A JP2021571993 A JP 2021571993A JP 2021571993 A JP2021571993 A JP 2021571993A JP 2022535429 A5 JP2022535429 A5 JP 2022535429A5
Authority
JP
Japan
Prior art keywords
cells
cell population
genetically modified
genetically
population according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535429A (ja
JP7629414B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035752 external-priority patent/WO2020247392A1/en
Publication of JP2022535429A publication Critical patent/JP2022535429A/ja
Publication of JP2022535429A5 publication Critical patent/JP2022535429A5/ja
Priority to JP2025015446A priority Critical patent/JP2025081360A/ja
Application granted granted Critical
Publication of JP7629414B2 publication Critical patent/JP7629414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571993A 2019-06-04 2020-06-02 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ Active JP7629414B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015446A JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962857167P 2019-06-04 2019-06-04
US62/857,167 2019-06-04
US201962943697P 2019-12-04 2019-12-04
US62/943,697 2019-12-04
PCT/US2020/035752 WO2020247392A1 (en) 2019-06-04 2020-06-02 Combinations of engineered natural killer cells and engineered t cells for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015446A Division JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Publications (3)

Publication Number Publication Date
JP2022535429A JP2022535429A (ja) 2022-08-08
JP2022535429A5 true JP2022535429A5 (enExample) 2023-06-09
JP7629414B2 JP7629414B2 (ja) 2025-02-13

Family

ID=73652681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571993A Active JP7629414B2 (ja) 2019-06-04 2020-06-02 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
JP2025015446A Pending JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015446A Pending JP2025081360A (ja) 2019-06-04 2025-01-31 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Country Status (7)

Country Link
US (1) US20220233593A1 (enExample)
EP (1) EP3980450A4 (enExample)
JP (2) JP7629414B2 (enExample)
CN (1) CN114174325A (enExample)
AU (1) AU2020288829A1 (enExample)
CA (1) CA3140393A1 (enExample)
WO (1) WO2020247392A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2021207795A1 (en) * 2020-01-13 2022-07-28 Nkarta, Inc. BCMA-directed cellular immunotherapy compositions and methods
AU2021286655A1 (en) * 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
WO2022040577A1 (en) * 2020-08-20 2022-02-24 City Of Hope Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022150392A1 (en) * 2021-01-05 2022-07-14 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
US20240166760A1 (en) * 2021-03-08 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MOLECULES THAT BIND TO CD66e POLYPEPTIDES
EP4326291A4 (en) * 2021-04-20 2025-03-12 Board of Regents, The University of Texas System Methods and compositions for genetic modification and therapeutic use of immune cells
WO2022242701A1 (en) * 2021-05-20 2022-11-24 Wuxi Biologics (Shanghai) Co., Ltd. Genetically modified gamma-delta t cells and uses thereof
CN117355600A (zh) * 2021-05-20 2024-01-05 上海药明生物技术有限公司 遗传修饰的nk细胞及其用途
US20240316102A1 (en) * 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
WO2023079082A1 (en) * 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
WO2023199961A1 (ja) * 2022-04-14 2023-10-19 第一三共株式会社 膜型サイトカイン及びｔｎｆ受容体スーパーファミリー分子の細胞内ドメインをコードするポリヌクレオチド
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
US20260021183A1 (en) * 2022-07-22 2026-01-22 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115948341B (zh) * 2022-11-28 2025-05-16 上海恩凯细胞技术有限公司 敲低nkg2a基因的car-免疫细胞及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
WO2012136231A1 (en) * 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
EP3326467B1 (en) * 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6681837B2 (ja) * 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
DK3143134T3 (da) * 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
CN116059378A (zh) * 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
AU2016249005B2 (en) * 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
EP3827838B1 (en) * 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
EP3423580A1 (en) * 2016-03-04 2019-01-09 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
EP3529268B1 (en) * 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
US20180100016A1 (en) * 2016-12-22 2018-04-12 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
JP2020503043A (ja) * 2016-12-30 2020-01-30 セルラリティ インコーポレイテッド 遺伝子改変されたナチュラルキラー細胞
BR112019019917A2 (pt) * 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
CN108728459B (zh) * 2017-04-24 2023-08-04 上海恒润达生生物科技股份有限公司 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
WO2019089884A2 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
EP3749770B9 (en) * 2018-02-09 2025-12-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Tethered interleukin-15 and interleukin-21
KR20210005240A (ko) * 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
CN110724199B (zh) * 2018-07-17 2023-12-05 成都盛世君联生物技术有限公司 Nkg2d car-t细胞及其制备和应用
MX2021006208A (es) * 2018-11-28 2021-10-01 Univ Texas Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
PE20211959A1 (es) * 2019-02-15 2021-09-30 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia
EP3773918A4 (en) * 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US11840575B2 (en) * 2019-05-07 2023-12-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting BCMA and their uses thereof
JP7724765B2 (ja) * 2019-07-31 2025-08-18 ンカルタ・インコーポレイテッド ナチュラルキラー細胞の増殖を亢進する、および細胞障害性を増強するための方法および組成物
CA3163258A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells

Similar Documents

Publication Publication Date Title
JP2022535429A5 (enExample)
JP2023530408A5 (enExample)
Kloess et al. CAR-expressing natural killer cells for cancer retargeting
JP2021530999A5 (enExample)
Kim et al. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells
JP2022548943A5 (enExample)
JP2022550899A5 (enExample)
JP2023552998A5 (enExample)
Morgan et al. Adoptive cell therapy: genetic modification to redirect effector cell specificity
Figueroa et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
CN115058395B (zh) 嵌合抗原受体(car)、组合物及其使用方法
JP2023505206A5 (enExample)
JP2021513347A5 (enExample)
TWI905347B (zh) 用於調變ｃａｒ－ｔ活性之方法與組成物
JP2021505131A5 (enExample)
JP2021519061A5 (enExample)
IL270415B2 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
Quandt et al. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
JP2022184852A5 (enExample)
JP2022510207A5 (enExample)
JP2022545167A5 (enExample)
JP2023516300A5 (enExample)
IL300729B2 (en) An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
JP2020511529A5 (enExample)